Variant | Gene | Disease | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
0.720 | GeneticVariation | BEFREE | In order to rigorously analyze the amount of cfDNA needed, we constructed 72 athymic nude mice xenografted with NCI-H1975 (harboring a EGFR T790M mutation) or NCI-H460 (harboring a KRAS Q61H mutation) human NSCLC. | 29497175 | 2018 |
||||||||
|
|
0.720 | GeneticVariation | BEFREE | The present studies demonstrate that silencing MUC1-C in A549/KRAS(G12S) and H460/KRAS(Q61H) NSCLC cells is associated with downregulation of AKT signaling and inhibition of growth. | 25245423 | 2014 |
||||||||
|
|
G | 0.720 | CausalMutation | CLINVAR | Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. | 18794081 | 2008 |
|||||||
|
|
A | 0.720 | CausalMutation | CLINVAR | Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. | 18794081 | 2008 |
|||||||
|
|
A | 0.720 | CausalMutation | CLINVAR | KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. | 15696205 | 2005 |
|||||||
|
|
G | 0.720 | CausalMutation | CLINVAR | KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. | 15696205 | 2005 |
|||||||
|
|
G | 0.720 | CausalMutation | CLINVAR | BRAF and RAS mutations in human lung cancer and melanoma. | 12460918 | 2002 |
|||||||
|
|
A | 0.720 | CausalMutation | CLINVAR | BRAF and RAS mutations in human lung cancer and melanoma. | 12460918 | 2002 |